Contineum (CTNM) CEO sells 2,500 shares under Rule 10b5-1 plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Contineum Therapeutics CEO Carmine N. Stengone reported an option exercise and share sale in Class A Common Stock. He exercised stock options for 2,500 shares at $1.01 per share and sold 2,500 shares at $16.00 per share on July 8, 2026. These trades were executed under a Rule 10b5-1 trading plan adopted on September 23, 2025. After the transactions, he holds 17,217 shares directly and 279,430 stock options expiring on February 24, 2030.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 2,500 shares ($40,000)
Net Sell
3 txns
Insider
Stengone Carmine N.
Role
CEO and President
Sold
2,500 shs ($40K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 2,500 | $0.00 | -- |
| Exercise | Class A Common Stock | 2,500 | $1.01 | $3K |
| Sale | Class A Common Stock | 2,500 | $16.00 | $40K |
Holdings After Transaction:
Stock Option (right to buy) — 279,430 shares (Direct, null);
Class A Common Stock — 19,717 shares (Direct, null)
Footnotes (1)
- These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. Options granted under the Issuer's 2012 Equity Incentive Plan (the "Plan"). The option is fully vested.
Key Figures
Shares sold: 2,500 shares
Sale price: $16.00/share
Options exercised: 2,500 options
+5 more
8 metrics
Shares sold
2,500 shares
Class A Common Stock sold at $16.00 on July 8, 2026
Sale price
$16.00/share
Open-market sale of 2,500 Class A shares
Options exercised
2,500 options
Exercised into Class A shares at $1.01 on July 8, 2026
Option exercise price
$1.01/share
Stock Option (right to buy) under 2012 Equity Incentive Plan
Shares held after
17,217 shares
Direct Class A Common holdings following transactions
Options remaining
279,430 options
Stock options outstanding after exercise, expiring February 24, 2030
Net share change
-2,500 shares
Net-sell direction from transaction summary
10b5-1 plan adoption date
September 23, 2025
Date CEO adopted trading plan used for these transactions
Key Terms
Rule 10b5-1 trading plan, Stock Option (right to buy), Equity Incentive Plan, Class A Common Stock, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
Equity Incentive Plan financial
"Options granted under the Issuer's 2012 Equity Incentive Plan (the "Plan")."
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
Class A Common Stock financial
"security_title: Class A Common Stock"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
derivative exercise/conversion financial
"transaction_action: derivative exercise/conversion"
FAQ
What insider transactions did CTNM CEO Carmine Stengone report?
CTNM CEO Carmine N. Stengone reported exercising stock options for 2,500 Class A shares and selling 2,500 shares. Both transactions occurred on July 8, 2026 and were disclosed in a Form 4 insider trading report.
Were the CTNM CEO’s trades made under a Rule 10b5-1 plan?
Yes. A footnote states the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on September 23, 2025. Such plans pre-schedule trades, helping separate routine liquidity events from discretionary market-timing decisions.
What stock options are involved in the CTNM CEO’s Form 4 filing?
The filing shows exercise of 2,500 stock options with a $1.01 exercise price, granted under the company’s 2012 Equity Incentive Plan. After this exercise, 279,430 options remain outstanding and are fully vested, expiring on February 24, 2030.